Core Viewpoint - Block & Leviton is investigating Wealthfront Corp. for potential securities law violations following significant net deposit outflows and disclosures regarding the CEO's stake in a new business venture [1][2]. Group 1: Company Performance - Wealthfront reported $208 million in net deposit outflows, a stark decline from the previous year's $874 million in inflows [2]. - The company's shares fell more than 15% on January 13, indicating a negative market reaction to the financial disclosures [2]. Group 2: Legal Investigation - Block & Leviton is looking into whether Wealthfront committed securities law violations and may pursue legal action to recover losses for affected investors [4]. - Investors who have lost money on their Wealthfront investments are encouraged to contact Block & Leviton for potential recovery options [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Wealthfront are invited to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 4: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Blue Owl Capital Inc. ("Blue Owl Capital Inc." or the "Company") (NYSE: OWL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Blue Owl Capital Inc. investors who were adversely affected by alleged securities fraud between February 6, 2025 and November 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra ...

Core Points - A class action lawsuit has been filed against CoreWeave, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][3] - Investors are encouraged to seek additional information regarding the lawsuit and their legal options [2][9] Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure [4] - The company relies on partnerships, including a merger agreement with Core Scientific, to develop its data centers [4] Allegations and Stock Performance - CoreWeave allegedly overstated its ability to meet customer demand and concealed significant construction delays at its data centers [5] - The stock price dropped significantly due to various announcements: - On October 30, 2025, the stock fell by $8.87 (over 6%) after the merger with Core Scientific was terminated [6] - On November 10, 2025, the stock dropped by $17.22 (over 16%) following lowered guidance for revenue and operational metrics due to construction delays [7] - On December 15, 2025, the stock decreased by $2.85 (over 3%) after reports of further delays in a major data center project [8]

New York, New York--(Newsfile Corp. - January 21, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI), certain of the Company's senior executives and directors, and underwriters of Fermi's Initial Public Offering after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Fermi, you are encouraged to obtain additional information by visiting: https://ww ...

MILWAUKEE, Jan. 20, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Chagee Holdings Limited (NASDAQ: CHA). The investigation results from inaccurate statements Chagee may have made regarding its business operations and prospects. Click here to join our investigation or to obtain additional information, or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. The investigation focuses on Chagee's representations with respe ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Corcept Therapeutics and its officers or directors following a significant stock price drop after the FDA's Complete Response Letter regarding relacorilant [1][3]. Group 1: Company Overview - Corcept Therapeutics Incorporated is a biopharmaceutical company focused on developing treatments for patients with conditions related to cortisol [3]. - The company’s stock price experienced a dramatic decline of $35.40 per share, or 50.42%, closing at $34.80 per share on December 31, 2025, after the FDA issued a Complete Response Letter for its New Drug Application for relacorilant [3]. Group 2: Regulatory Developments - On December 31, 2025, the FDA issued a Complete Response Letter regarding Corcept's New Drug Application for relacorilant, indicating that while the pivotal GRACE trial met its primary endpoint, additional evidence of effectiveness was required for a favorable benefit-risk assessment [3].

Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of AST SpaceMobile, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [2]. Group 1: Investigation Details - The investigation focuses on whether AST SpaceMobile and certain officers or directors have engaged in securities fraud or other unlawful business practices [2]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance and Analyst Actions - On January 7, 2026, Scotiabank downgraded AST SpaceMobile to a "Sell" rating, citing significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites [4]. - Following the downgrade, AST's stock price fell by $11.76 per share, or 12.06%, closing at $85.73 per share on the same day [4].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 13, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased CoreWeave, Inc. ("CoreWeave†or the "Company†) (NASDAQ: CRWV) securities between March 28, 2025 and December 15, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN COREWEAVE, INC. (CRWV), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURIT ...

Core Viewpoint - Sigma Lithium Corporation is under investigation for potential securities fraud and unlawful business practices, following a downgrade by Bank of America due to unresolved operational and liquidity issues [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of Sigma Lithium investors regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action [2]. Group 2: Stock Performance and Analyst Downgrade - On January 8, 2026, Bank of America downgraded Sigma Lithium from Neutral to Underperform, citing unresolved operational and liquidity issues [3]. - Following the downgrade, Sigma Lithium's stock price decreased by $2.36 per share, or 15.07%, closing at $13.30 per share on the same day [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, following a significant stock price drop after the FDA's Complete Response Letter regarding its EBVALLO™ treatment [1][3]. Group 1: Company Overview - Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is under investigation for possible securities fraud or other unlawful business practices [1]. - The company recently faced a setback when the FDA issued a Complete Response Letter for its EBVALLO™ Biologics License Application, indicating that the application could not be approved in its current form [3]. Group 2: FDA Response and Impact - The FDA's Complete Response Letter stated that the single-arm ALLELE trial, previously deemed adequate for the BLA filing, is now considered insufficient for demonstrating effectiveness for accelerated approval [3]. - Following the FDA's announcement, Atara's stock price plummeted by $7.79 per share, a decrease of 56.99%, closing at $5.88 per share on January 12, 2026 [3].